February 22, 2011 -- Biomics Biotechnologies of Nantong and Benitec Limited of Australia agreed to advance their hepatitis B anti-viral collaboration into in vivo pre-clinical studies. The two companies are seeking to identify an RNA interference (RNAi) treatment for hepatitis B. Both companies are RNAi specialists. More details....
Stock Symbol: (ASX: BLT)
